Modulation of Brain Blood Flow Using Dichoptic Visual and Auditory Stimulation

Cerebral Arterial Diseases Clinical Trial

Official title:

Modulation of Brain Blood Flow Using Dichoptic Visual and Auditory Stimulation

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT03632564
• Other study ID #: SMC-5167-18
• Status: Not yet recruiting
• Phase: N/A
• Start date: October 10, 2018
• Est. completion date: August 15, 2019

Study information

• Verified date: August 2018
• Source: Visior Technologies Ltd.
• Contact: Arie Orenstain, Prof.
• Phone: 972-3-5302993
• Email: Arie.Orenstain[@]sheba.health.gov.il
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Modulation of brain blood flow using dichoptic Visual and Auditory stimulation using REVIVIEW system will be evaluated.

Description:

The participant will undergo baseline MRI to measure blood flow in the brain for comparison later on. After baseline MRI, the participant will observe stimulation using the REVIVIEW system for 20 minutes. The content the participants will see is a nature documentary, after which the participant will undergo additional MRI imaging to assess the change in blood flow in the brain.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 10
• Est. completion date: August 15, 2019
• Est. primary completion date: July 15, 2019
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• healthy subjects

Exclusion Criteria:

• History of brain diseases

• Glasses

• Diagnosed with Diabetes

• Diagnosed with Degenerative brain diseases

• Inability to undergo MRI

Related Conditions & MeSH terms

• Cerebral Arterial Diseases

Intervention

Device:
• REVIVIEW dichoptic audio-visual stimulation
REVIVIEW dichoptic audio-visual stimulation using video goggles

Locations

Country	Name	City	State
Israel	Sheba Medical Center	Ramat Gan

Sponsors (1)

Lead Sponsor	Collaborator
Visior Technologies Ltd.

Country where clinical trial is conducted

Israel, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in blood flow in the brain in respond to the stimulation	Evaluate the change in blood flow in different parts of the brain, compared with baseline, after the cessation of stimulation, after 30 minutes and after 60 minutes.	1 hour